Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mary N. Berkaw is active.

Publication


Featured researches published by Mary N. Berkaw.


Molecular & Cellular Proteomics | 2006

Identification of the Major Site of O-Linked β-N-Acetylglucosamine Modification in the C Terminus of Insulin Receptor Substrate-1

Lauren E. Ball; Mary N. Berkaw; Maria G. Buse

Signal transduction from the insulin receptor to downstream effectors is attenuated by phosphorylation at a number of Ser/Thr residues of insulin receptor substrate-1 (IRS-1) resulting in resistance to insulin action, the hallmark of type II diabetes. Ser/Thr residues can also be reversibly glycosylated by O-linked β-N-acetylglucosamine (O-GlcNAc) monosaccharide, a dynamic posttranslational modification that offers an alternative means of protein regulation to phosphorylation. To identify sites of O-GlcNAc modification in IRS-1, recombinant rat IRS-1 isolated from HEK293 cells was analyzed by two complementary mass spectrometric methods. Using data-dependent neutral loss MS3 mass spectrometry, MS/MS data were scanned for peptides that exhibited a neutral loss corresponding to the mass of N-acetylglucosamine upon dissociation in an ion trap. This methodology provided sequence coverage of 84% of the protein, permitted identification of a novel site of phosphorylation at Thr-1045, and facilitated the detection of an O-GlcNAc-modified peptide of IRS-1 at residues 1027–1073. The level of O-GlcNAc modification of this peptide increased when cells were grown under conditions of high glucose with or without chronic insulin stimulation or in the presence of an inhibitor of the O-GlcNAcase enzyme. To map the exact site of O-GlcNAc modification, IRS-1 peptides were chemically derivatized with dithiothreitol following β-elimination and Michael addition prior to LC-MS/MS. This approach revealed Ser-1036 as the site of O-GlcNAc modification. Site-directed mutagenesis and Western blotting with an anti-O-GlcNAc antibody suggested that Ser-1036 is the major site of O-GlcNAc modification of IRS-1. Identification of this site will facilitate exploring the biological significance of the O-GlcNAc modification.


Molecular & Cellular Proteomics | 2009

O-Linked N-Acetylglucosamine Modification of Insulin Receptor Substrate-1 Occurs in Close Proximity to Multiple SH2 Domain Binding Motifs

Amanda Leigh Klein; Mary N. Berkaw; Maria G. Buse; Lauren Ball

Insulin receptor substrate-1 (IRS-1) is a highly phosphorylated adaptor protein critical to insulin and IGF-1 receptor signaling. Ser/Thr kinases impact the metabolic and mitogenic effects elicited by insulin and IGF-1 through feedback and feed forward regulation at the level of IRS-1. Ser/Thr residues of IRS-1 are also O-GlcNAc-modified, which may influence the phosphorylation status of the protein. To facilitate the understanding of the functional effects of O-GlcNAc modification on IRS-1-mediated signaling, we identified the sites of O-GlcNAc modification of rat and human IRS-1. Tandem mass spectrometric analysis of IRS-1, exogenously expressed in HEK293 cells, revealed that the C terminus, which is rich in docking sites for SH2 domain-containing proteins, was O-GlcNAc-modified at multiple residues. Rat IRS-1 was O-GlcNAc-modified at Ser914, Ser1009, Ser1036, and Ser1041. Human IRS-1 was O-GlcNAc-modified at Ser984 or Ser985, at Ser1011, and possibly at multiple sites within residues 1025–1045. O-GlcNAc modification at a conserved residue in rat (Ser1009) and human (Ser1011) IRS-1 is adjacent to a putative binding motif for the N-terminal SH2 domains of p85α and p85β regulatory subunits of phosphatidylinositol 3-kinase and the tyrosine phosphatase SHP2 (PTPN11). Immunoblot analysis using an antibody generated against human IRS-1 Ser1011 GlcNAc further confirmed the site of attachment and the identity of the +203.2-Da mass shift as β-N-acetylglucosamine. The accumulation of IRS-1 Ser1011 GlcNAc in HEPG2 liver cells and MC3T3-E1 preosteoblasts upon inhibition of O-GlcNAcase indicates that O-GlcNAcylation of endogenously expressed IRS-1 is a dynamic process that occurs at normal glucose concentrations (5 mm). O-GlcNAc modification did not occur at any known or newly identified Ser/Thr phosphorylation sites and in most cases occurred simultaneously with phosphorylation of nearby residues. These findings suggest that O-GlcNAc modification represents an additional layer of posttranslational regulation that may impact the specificity of effects elicited by insulin and IGF-1.


Molecular & Cellular Proteomics | 2013

Identification of O-Linked N-Acetylglucosamine (O-GlcNAc)-modified Osteoblast Proteins by Electron Transfer Dissociation Tandem Mass Spectrometry Reveals Proteins Critical for Bone Formation

Alexis K. Nagel; Michael Schilling; Susana Comte-Walters; Mary N. Berkaw; Lauren E. Ball

The nutrient-responsive β-O-linked N-acetylglucosamine (O-GlcNAc) modification of critical effector proteins modulates signaling and transcriptional pathways contributing to cellular development and survival. An elevation in global protein O-GlcNAc modification occurs during the early stages of osteoblast differentiation and correlates with enhanced transcriptional activity of RUNX2, a key regulator of osteogenesis. To identify other substrates of O-GlcNAc transferase in differentiating MC3T3E1 osteoblasts, O-GlcNAc-modified peptides were enriched by wheat germ agglutinin lectin weak affinity chromatography and identified by tandem mass spectrometry using electron transfer dissociation. This peptide fragmentation approach leaves the labile O-linkage intact permitting direct identification of O-GlcNAc-modified peptides. O-GlcNAc modification was observed on enzymes involved in post-translational regulation, including MAST4 and WNK1 kinases, a ubiquitin-associated protein (UBAP2l), and the histone acetyltransferase CREB-binding protein. CREB-binding protein, a transcriptional co-activator that associates with CREB and RUNX2, is O-GlcNAcylated at Ser-147 and Ser-2360, the latter of which is a known site of phosphorylation. Additionally, O-GlcNAcylation of components of the TGFβ-activated kinase 1 (TAK1) signaling complex, TAB1 and TAB2, occurred in close proximity to known sites of Ser/Thr phosphorylation and a putative nuclear localization sequence within TAB2. These findings demonstrate the presence of O-GlcNAc modification on proteins critical to bone formation, remodeling, and fracture healing and will enable evaluation of this modification on protein function and regulation.


Molecular & Cellular Proteomics | 2013

Identification of O-GlcNAc modified osteoblast proteins by electron transfer dissociation tandem mass spectrometry reveals proteins critical for bone formation

Alexis K. Nagel; Michael Schilling; Susana Comte-Walters; Mary N. Berkaw; E Lauren

The nutrient-responsive β-O-linked N-acetylglucosamine (O-GlcNAc) modification of critical effector proteins modulates signaling and transcriptional pathways contributing to cellular development and survival. An elevation in global protein O-GlcNAc modification occurs during the early stages of osteoblast differentiation and correlates with enhanced transcriptional activity of RUNX2, a key regulator of osteogenesis. To identify other substrates of O-GlcNAc transferase in differentiating MC3T3E1 osteoblasts, O-GlcNAc-modified peptides were enriched by wheat germ agglutinin lectin weak affinity chromatography and identified by tandem mass spectrometry using electron transfer dissociation. This peptide fragmentation approach leaves the labile O-linkage intact permitting direct identification of O-GlcNAc-modified peptides. O-GlcNAc modification was observed on enzymes involved in post-translational regulation, including MAST4 and WNK1 kinases, a ubiquitin-associated protein (UBAP2l), and the histone acetyltransferase CREB-binding protein. CREB-binding protein, a transcriptional co-activator that associates with CREB and RUNX2, is O-GlcNAcylated at Ser-147 and Ser-2360, the latter of which is a known site of phosphorylation. Additionally, O-GlcNAcylation of components of the TGFβ-activated kinase 1 (TAK1) signaling complex, TAB1 and TAB2, occurred in close proximity to known sites of Ser/Thr phosphorylation and a putative nuclear localization sequence within TAB2. These findings demonstrate the presence of O-GlcNAc modification on proteins critical to bone formation, remodeling, and fracture healing and will enable evaluation of this modification on protein function and regulation.


International Journal of Clinical & Laboratory Research | 1992

Molecular cloning and sequence analysis of the cDNA encoding human apolipoprotein H (beta 2-glycoprotein I).

Joseph R. Day; Patrick J. O'Hara; Francis J. Grant; Catherine E. Lofton-Day; Mary N. Berkaw; Phillip Werner; Philippe Arnaud

SummaryApolipoprotein H, also known as β-2-glycoprotein I, was purified from human serum, and antiserum produced to denatured apolipoprotein H detected a cDNA clone from a γ gt11 library derived from human liver. This cDNA coded for the complete sequence of the mature protein. The cDNA insert, along with a polymerase chain reaction product which extended the 5′ end of the message, were subcloned and both strands were sequenced. The apolipoprotein H precursor was found to code for 345 amino acids, 326 of which appear in the mature protein. The deduced amino acid sequence of human apolipoprotein H differs from its rat homologue by the presence of a 48-amino acid stretch which is absent from the rat protein. The remainder of the proteins share a greater than 80% similarity. The amino acid sequence of apolipoprotein H consists largely of repeated units approximately 60 amino acids in length. These repeats are comparable to “sushi structures” found in a large number of diverse proteins, including complement components, receptors and regulators of complement activation, serum proteins, membrane-associated adhesion proteins, and other structural and catalytic proteins. Apolipoprotein H was shown to be transcribed by human hepatoma cell lines Hep 3B and Hep G2, and rat liver by detection of mRNA using northern blot analysis.


Methods | 2016

Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics.

Grace R. Williams; Jennifer R. Bethard; Mary N. Berkaw; Alexis K. Nagel; Louis M. Luttrell; Lauren E. Ball

The type 1 parathyroid hormone receptor (PTH1R) is a key regulator of calcium homeostasis and bone turnover. Here, we employed SILAC-based quantitative mass spectrometry and bioinformatic pathways analysis to examine global changes in protein phosphorylation following short-term stimulation of endogenously expressed PTH1R in osteoblastic cells in vitro. Following 5min exposure to the conventional agonist, PTH(1-34), we detected significant changes in the phosphorylation of 224 distinct proteins. Kinase substrate motif enrichment demonstrated that consensus motifs for PKA and CAMK2 were the most heavily upregulated within the phosphoproteome, while consensus motifs for mitogen-activated protein kinases were strongly downregulated. Signaling pathways analysis identified ERK1/2 and AKT as important nodal kinases in the downstream network and revealed strong regulation of small GTPases involved in cytoskeletal rearrangement, cell motility, and focal adhesion complex signaling. Our data illustrate the utility of quantitative mass spectrometry in measuring dynamic changes in protein phosphorylation following GPCR activation.


Human Genetics | 1995

Restriction polymorphisms of the ceruloplasmin gene on chromosome 3.

Muriel Bost; Mary N. Berkaw; O.Wesley McBride; Guy Chazot; Philippe Arnaud

Using a probe isolated from a human liver cDNA library, polymorphisms were observed in the human ceruloplasmin gene with the enzymes PstI and MspI. The PstI polymorphism was frequent (allele frequencies, 0.46 and 0.54) whereas the polymorphisms found with MspI were rare.


Protides of the biological fluids | 1989

Isolation and Charcterization of the Protein and cDNA For β2-Glycoprotein I (Apolipoprotein H)

J. Day; Mary N. Berkaw; Philippe Arnaud

Abstract β2-Glycoprotein I (β2I) is a plasma glycoprotein with a normal concentration near 0.2 mg/ml. It is a component of circulating plasma lipoproteins, enhances triglyceride clearance, binds to platelets, and activates lipoprotein lipase. Since β2I fulfills the criteria of apolipoproteins, it is also called apolipoprotein-H (Apo H) We attempted screening an expression library using commercial antisera to clone a β2I insert which would be used to conduct expression studies using hepatocytes and hepatoma cell lines. Screening up to 106 plaques revealed a low number of weakly positive clones. Sanger dideoxy sequencing demonstrated that their sequence did not translate into the known protein sequence of β2I. The antisera demonstrated a good titer and monospecificity to serum β2I, but recognized only nonreduced and completely failed to recognize reduced serum β2I upon Western blot analysis We therefore designed a two step protocol for the isolation of β2I from human serum using pseudo-ligand affinity chromatography and nonreducing preparative SDS-PAGE. The electo-eluted β2I was then reduced and used to immunize a rabbit. The antiserum produced was monospecific and reacted with both reduced and nonreduced β2I. It was able to unambiguously detect several positive clones upon rescreening of the same library. This demonstrates that eukaryotic proteins may undergo important changes in tertiary structure when expressed in prokaryotic systems and that in this case it was advantageous to produce antisera to the denatured protein


American Journal of Physiology-endocrinology and Metabolism | 2006

Glucose, dexamethasone, and the unfolded protein response regulate TRB3 mRNA expression in 3T3-L1 adipocytes and L6 myotubes

Sherif Z. Yacoub Wasef; Katherine A. Robinson; Mary N. Berkaw; Maria G. Buse


The FASEB Journal | 2015

O-GlcNAc Modification of Runx2 Links Nutrient Metabolism with Osteogenesis

Alexis K. Nagel; Mary N. Berkaw; Lauren E. Ball

Collaboration


Dive into the Mary N. Berkaw's collaboration.

Top Co-Authors

Avatar

Alexis K. Nagel

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Lauren E. Ball

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Maria G. Buse

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael Schilling

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Philippe Arnaud

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Katherine A. Robinson

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Susana Comte-Walters

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

E Lauren

Medical University of South Carolina

View shared research outputs
Researchain Logo
Decentralizing Knowledge